肿瘤细胞治疗研究
英文原题：CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
CD30 是肿瘤坏死因子受体超家族的一种跨膜蛋白。
CD30是一种跨膜蛋白，属于肿瘤坏死因子受体超家族。它在少数活化T、B淋巴细胞及多种淋巴系统肿瘤中表达。CD30是颇具吸引力的治疗靶点，因为其在肿瘤中高表达、在健康组织中表达较低。研究者已开发多种靶向CD30的治疗策略，包括单克隆抗体、偶联抗体（如维布妥昔单抗联合化疗或免疫治疗）、双特异性抗体，以及细胞和基因疗法，尤其是抗CD30 CAR-T细胞。本文简要综述CD30的生物学特征及其成为理想治疗靶点的原因，并介绍迄今出现的所有抗CD30疗法。
CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CAR-T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.
MEMBER ACCOUNT
登录成功会直接打开下一页。
